Possible Clinical Applications of Tumour-associated Antigens
The assay and identification of human tumourassociated antigens may promise new prospects in oncological medicine for the development of immunotherapeutic regimes and methods of detecting tumours together with their improved pathological classification.
One area of possible use lies in their facilitating tumour diagnosis, especially its earlier diagnosis and in improving clinical differentiation of neoplastic and non-neoplastic disorders. If successful therapy, such as surgical removal of the tumour, is associated with a return to normal levels of tumour-associated products in the body fluids, then their sequential assay during the follow-up phase may reveal rising titres which will enable recurrences to be detected earlier than by other clinical means. If therapy is instituted at that time, better survival rates may be achieved. Measurement of HCG levels in the plasma of patients with choriocarcinoma has proved to be a valuable aid in detecting residual tumour and in assessing the adequacy of therapeutic measures (Bagshawe, 1969) . This line of investigation seems to be worthy of study using tumour-associated antigens as the index substances.
The detection of these antigens or their effects upon the immune system may have importance in the field of histopathology. At present, most tumours are classified histogenetically and behaviouristically, functional attributes, except for endocrine tumours, seldom being included. By outlining the tumourassociated antigens associated with a particular lesion, functional heterogeneity or homogeneity between tumours of identical or different morphology may be discerned which could have aetiological, behavioural, and prognostic significance.
In this communication, I will attempt to illustrate some of those aspects from our present knowledge of three tumour-associated antigens, namely, two oncofetal antigens, alpha-fetoprotein (AFP) (Abelev et al, 1963) and the carcinoembryonic antigen (CEA) (Gold and Freedman, 1965a and b) , and the cancer basic protein (Carnegie, Caspary, and Field, 1972 Abelev et al (1963) and in patients with hepatocellular carcinomas, by Tatarinov (1965) . Subsequent studies have shown AFP to be a single chain alphal-globulin (molecular weight 64 000) containing 4 % carbohydrate and which may exist in monomeric and dimeric forms (Nishi, 1970) ; Ruoslahti, Sepalla, Pikko, and Vuopio, 1971) . Amino acid analyses have revealed that AFP and albumin are closely related proteins and that the alpha-fetoproteins extracted from fetal serum or from hepatomas are similar in amino acid composition (Nishi, 1970; Abelev, 1971; .
Alpha-fetoprotein has been quantitated by different immunological techniques, including immunodiffusion (sensitivity of between 1 and 3 ,ug/ml serum), immunoautoradiography (sensitivity, 50 ng/ml serum) ) and radioimmunoassay (sensitivity, 025 ng/ml serum) . It is formed principally by the fetal liver and also by the yolk sac and gastrointestinal tract (Gitlin and Boesman, 1967; Engelhardt, Shipova, Gusev, Yazova, and Ter-Grigorova, 1969; Gitlin and Pericelli, 1970; Gitlin, 1971) . In the liver, most hepatocytes are initially involved in its synthesis by the sixth week of fetal life. The serum levels reach a peak, of the order of 3 to 4 mg/ml, about the thirteenth week of intrauterine life. Thereafter, the levels fall while albumin concentrations rise; these changes are paralleled by a decline in the number of AFP-forming hepatocytes which then tend to be concentrated around the central vein (Engelhardt et al, 1969) . Small amounts of AFP continue to be formed by healthy adults, the detection of which requires radioimmunoassay; normal serum levels are below 10 ng/ml .
CARCINOEMBRYONIC ANTIGEN
In 1965, Gold and Freedman described the presence of a tumour antigen in primary adenocarcinomas of the human colon but not in autologous uninvolved colonic mucosa. It was also found in the embryonic gastrointestinal tract, liver, and pancreas during the first two trimesters of pregnancy and accordingly was called the carcinoembryonic antigen (Gold and Freedman, 1965a and b) .
Detailed chemical studies of the structure of CEA are in progress and have already shown that it is a water-soluble glycoprotein with a molecular weight of approximately 200 000 and that it differs in its amino acid and carbohydrate composition from blood group substances Freeman, 1967, 1968; Turberville, James, Darcy, Pelly, Johns, and Neville, 1973) . Carcinoembryonic antigen is associated with the glycocalyx (cell coat) of the cell membrane and is detected in particular on the luminal aspect of neoplastic cells (von Kleist and Burtin, 1969) . The development of sensitive radioimmunoassays for CEA (Thomson, Krupey, Freedman, and Gold, 1969 ; Lo Gerfo, Krupey, and Hansen, 1971; Egan, Lautenschleger, Coligan, and Todd, 1972) has shown that small amounts of CEA exist in some normal adult digestive tract tissues (Martin and Martin, 1970; Darcy, Turberville, and James, 1973) and that nanogram levels are detectable in the body fluids of healthy adults (Hall, Laurence, Darcy, Stevens, James, Roberts, and Neville, 1972; Lo Gerfo, Herter, and Bennett, 1972) .
CANCER BASIC PROTEIN Field and Caspary (1970) , using a macrophage electrophoretic mobility test, reported that the lymphocytes of patients with malignant tumours were sensitized to the encephalitogenic factor (EF). This cell-mediated immune phenomenon, also observed in patients suffering from destructive neurological disorders, led them to attempt the isolation of a macromolecule closely related to encephalitogenic factor from malignant tumours. A water-soluble basic protein with a molecular weight of approximately 16 000 has been identified in the plasma membrane of tumour cells (Carnegie et al, 1972) . Like encephalitogenic factor, it contains a single tryptophan residue which is necessary for its antigenicity, but. using immunological and pharmacological methods, differences between encephalitogenic factor and the cancer basic protein are identifiable Caspary, 1972; Field, Caspary, and Carnegie, 1971 Field and Caspary (1970) Fibroadenoma of breast 3 1 0 Caspary (1972) Benign hypertrophy (Caspary, 1972) . This ability of the test to detect precocious lymphocyte sensitivity before the tumour becomes clinically overt has also been revealed by finding positive reactions in children born many years before their mothers apparently developed clinically overt carcinomas (Field and Caspary, 1971b) .
False negative results can arise because of radiotherapy, extensive metastatic disease, lymphatic leukaemia, and in those rare individuals who fail to exhibit any type of antigenic response Caspary, 1971a, 1972) , whilst false positive reactions can occur in patients with a variety of disorders including sarcoidosis, tuberculosis, intrinsic asthma, rheumatoid arthritis, DLE, exposure to the influenza viruses, and destructive neurological disease.
If the initial promise is maintained after adequate follow up in the future of patients with inflammatory and regenerative disorders, benign tumours and precancerous conditions, detection of sensitivity to this basic protein may offer real assistance to early diagnosis and differential diagnosis.
At present, AFP is detected most commonly by gel diffusion methods and the expected incidence of positive assays and their value in tumour diagnosis can be seen in table II. With this technique, raised AFP levels are remarkably specific for hepatocellular carcinoma and malignant teratomas. Other carcinomas tend only to result in positive assays once they have metastasized to the liver (O'Conor, Tatarinov, Abelev, and Uriel, 1970; Alpert, Pinn, and Isselbacher, 1971; Kozower, Fawaz, Miller, and Kaplan, 1971; Mehlman, Bulkley, and Wiernik, 1971) .
Using the increased sensitivity of AFP radio- Whilst initial studies suggested that elevated plasma CEA levels were specific for endodermally derived carcinomas (Thomson et al, 1969) . Of especial interest and potential clinical importance has been the finding of raised CEA levels in the urine of patients with urothelial carcinoma (Hall et al, 1972) . The assay of plasma CEA seems to have most clinical application in the diagnosis of carcinomas of the gastrointestinal tract, pancreas, and bronchus, approximately 70-92% of which will yield raised values (table III) . It is also of value in the assessment of neuroblastoma and possibly mammary carcinoma (table III) but has little or no part to play in the diagnosis of tumours at other sites .
The component cell types of tumours or the degree of their structural differentiation do not seem to influence the level of plasma CEA . This is determined more by the extent of tumour spread (table IV) .
Using the assay of Egan et al (1972) , it is possible to divide the plasma CEA levels into three groups, namely, normal (<12-5 ng/ml), intermediate (12-5-40 ng/ml), and high (>40 ng/ml) . Whilst patients with benign and malignant tumours and with inflammatory or regenerative disorders may fall into either the normal or intermediate groups, levels in excess of 40 ng/ml are nearly always diagnostic of a malignant tumour Urinary CEA levels are normal in association with non-urothelial tumours, such as hypernephroma and prostatic carcinoma, even when plasma levels are raised. Only when such tumours involve the urinary tract by infiltration, do the urine levels rise. Accordingly, elevated urinary CEA levels are specific to urothelial carcinomas provided urinary infection can be excluded (Hall et al, 1972 ; table V). The degree of structural tumour differentiation does not influence the level of urinary CEA (Hall et al, 1972) and high levels occur with all stages of the disease (table VI) . Thus, it can be seen that well differentiated tumours in situ, which are difficult to detect by urinary exfoliative cytology, may be associated with raised levels. Consequently, urinary CEA assays could be important in the screening of highrisk population groups such as those in the rubber or dye industries.
Role in Management of Patients in Follow-up Phase
The aspect of plasma CEA estimations which is attracting most current attention is its role in the detection of residual neoplastic disease and in the development of metastases. If the plasma CEA is raised preoperatively, complete tumour removal is associated with a decline to normal levels between the second and eighteenth postoperative days; a remaining high level indicates residual disease (Dhar, Moore, Zamchek, and Kupchick, 1972; Holyoke, Reynoso, and Chu, 1972; . We are at present examining a large group of patients in the follow-up phase after surgical treatment for colorectal carcinoma and our experience to date, and that of Dhar et al (1972) , indicate that the development of recurrent and/or metastatic disease is most often associated with a rise of CEA to pathological levels. Moreover, such a rise can occur in advance of clinically detectable tumour (fig) .
Plasma CEA levels are raised in only a minority of patients with localized bladder carcinomas, but with extravesical or pelvic spread, the incidence of raised values increases (table IV) (O time) and with the development of confirmed metastatic tumour in two of the three patients.
of both the urinary and plasma CEA in the followup phase after treatment may be of value in facilitating the detection of local and distant recurrences of urothelial carcinomas.
Little attention has been paid to this aspect of the clinical role of AFP assays. However, there is evidence in animals and man to suggest that the development of hepatomas may be preceded by rises in AFP serum levels and that recurrences are associated with coincident rises in AFP values to reach previous or even higher levels (Houstek, Masopust, Kithier, and Radl, 1968; Hull, Carbone, Gitlin, O'Gara, and Kelly, 1969; Mawas, Kohen, Lemerle, Buffd, Schweisguth, and Burtin, 1969; Khazanov, Abelev, Perova, Polenko, Ryapsova, and Shirenkova, 1971; Watabe, 1971; Braunstein, Bridson, Glass, Hull, and McIntire, 1972; McIntire, Vogel, Princler, and Patel, 1972) .
Role in Assessing the Effects of Therapy
Both AFP and CEA have been employed as biochemical index substances to assess the effects of chemotherapy.
Successful therapy, including chemotherapy for hepatocarcinoma and teratocarcinoma, is associated with a decline in AFP levels which rise again with the development of recurrences (Mawas et al, 1969) . Clinical improvement may be matched by falls in AFP levels but in several patients a decline in AFP values was not accompanied by any clinical response (Purves, Bersohn, and Geddes, 1970) .
Holyoke and his associates (1972) have employed plasma CEA levels to monitor the effectiveness of chemotherapy. They reported that a favourable clinical response with a marked decrease in tumour size was associated with a decline of the CEA levels in plasma to normal. Relapse subsequently occurred and was preceded by a rise of CEA levels to pathological levels. These interesting observations need further study, but are of potential importance to the chemotherapist and radiotherapist.
A recent example of a hepatoblastoma secreting both HCG and AFP emphasizes the importance of trying to measure as many biochemical indices as possible for every tumour. Braunstein et al (1972) noted discordance between HCG and AFP levels in response to chemo-and/or radiotherapy which suggested that different cell lines in the same tumour may display differential responses.
Role in Assessing Prognosis Mawas et al (1969) have commented that patients with raised AFP levels have more aggressive teratocarcinomas whilst the majority of AFP-negative malignant teratomas respond to therapy. This may represent a valuable prognostic aid in assessing tumours which may appear to be equally 'malignant' on morphological grounds. This relationship does not appear to be the case in patients with hepatomas where the levels seem to be independent of tumour size, stage, or differentiation (Purves, Macnab, and Bersohn, 1968) . It is not yet known if patients with localized tumours and high CEA levels in the plasma or urine pursue a better or worse course than those whose tumours are associated with normal CEA values. Recent experimental evidence suggests the possible importance of ascertaining this point. Kim and Carruthers (1972) examined two strains of experimental breast carcinoma which differed in their metastasizing potential. They found an inverse relationship between the presence of an antigen not necessarily CEA in the glycocalyx of the tumour cells and its concentration in serum. As the surface glycoprotein declined in amount and level in plasma rose, the metastasizing potential increased.
Conclusions and Prospects
The presence of tumour-associated macromolecules in association with human tumours is now well established. They occur within or on the cell surface and may be released into the body fluids. Many are also known to be present in fetal tissues and some possess biological activity .
Numerous further tumour-associated antigens will almost certainly be identified in the next few years, and it is imperative that the relationship of one material to another and their possible role in clinical practice are examined in an integrated and meaningful manner.
None of the presently recognized tumour-associated principles are specific for malignant tumours, quantitative rather than qualitative differences exist among inflammatory disorders, benign and malignant tumours. Nonetheless, such materials have a clinical role at this time, assisting in tumour diagnosis and monitoring the effects of therapy.
It seems worthwhile in the future to attempt to measure as many as possible of the known tumourassociated principles including the 'ectopic' hormones. In this way, a battery of tests will be available which, when viewed together, may improve tumour detection and its differential diagnosis. Finally, by outlining such spectra, functional heterogeneity between tumours of identical light morphology or between cells of the same tumour may be observed which could have behaviouristic, histogenetic, and aetiological significance.
